Health Economics›Breast cancer›HER2-positive first-line therapy

HER2-positive first-line therapy

Breast cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine and Lapatinib Variant #01	—	R 24 587	21d	~6.8 mo	~21.6 mo	~2	~R 49 173 PFS proxy · indirect	7
Capecitabine and Trastuzumab (XH) Variant #01	—	R 15 097	21d	9.9 mo	—	3	R 21 861 PFS proxy	2

2 of 2 regimens shown